Case Report

Concomitant Essential Thrombocythemia and Mature B -Lymphoproliferative Disorder in a Patient

ET and LPD

Abstract

A-64-year old male presented with cough, weight loss, and maculopapular rash for 15-20 days. On examination, he was found to have cervical lymphadenopathy and splenomegaly. His leukocyte count was 62.1x109/L, platelets were 1169x109/L and LDH was 816 IU/L. Peripheral blood film showed a leukoerythroblastic picture with thrombocytosis. He was started on hydroxyurea and allopurinol. Subsequently, bone marrow evaluation was done which depicted increased lymphoid cells with an M:E ratio of 4:1. Cellular areas exhibited an increase in myeloid precursors along with prominent lymphoid cells and abundant megakaryocytes. Immunohistochemistry showed an increase in B-lymphocytes. Grade MF-2 reticulin fibrosis was noted. Overall findings suggested essential thrombocythemia (ET). On flow cytometry, CD45-positive lymphoid cells population was 31% and showed reactivity to Pan-B-markers with lambda light chain restriction. Janus Kinase (JAK) 2 mutation was detected while BCR-ABL1 translocation was negative. A diagnosis of ET progressing to myelofibrosis and mature B-lymphoproliferative disorder was made. Hydroxyurea and allopurinol were stopped while ruxolitinib was introduced and 2.5 years later he remains stable on this treatment.

1. Aquino-Esquadro L, Mehendale S, Kadkol S, et al. JAK2 V617F Positive Essential Thrombocythemia Complicated by B-cell Chronic Lymphocytic Leukemia: An Uncommon Association and Diagnostic Pitfall. Lab Med. 2011;42(2):83-5.
2. Robak T, Urbańska-Ryś H, Gora-Tybor J, et al. Coexistence of chronic lymphocytic leukemia and essential thrombocythemia. Leuk Lymphoma. 2003; 44(8): 1425-31.
3. Hasskarl J, Ihorst G, De Pasquale D, et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leuk Lymphoma. 2011;52(2):247–59.
4. Miranda MB, Lauseker M, Kraus M-P, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML study IV. Leukemia. 2016;30(6): 1255–62.
5. Call TG, Phyliky RL, Noel P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994;69(4):323–8.
6. Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014; 55(3):595-600
7. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29.
8. Tefferi A. Polycythemia vera and essential thrombocythemia:2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(6):507-16
9. Gargallo P, Cacchione R, Chena C, et al.Chronic lymphocytic leukemia developing in a patient with chronic myeloid leukemia: evidence of distinct lineage-associated genomic events. Cancer Genet Cytogenet. 2005; 161(1):74-7.
10. Greene MH, Hoover RN, Fraumeni Jr J F.Subsequent cancer in patients with chronic lymphocytic leukemia: a possible immunologic mechanism. J Natl Cancer Inst. 1978; 61(2):337-40.
11. Chintapatla R, Battini R, Wiernik PH. Chronic lymphocytic leukemia with essential thrombocythemia: asbestos exposure association?. Clin Adv Hematol Oncol. 2012;10(11):752-5.
12. Laurenti L, Tarnani M, Nichele I, et al. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hemato. 2011; 86(12):1007-12.
13. Vannucchi M, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev.2009; 18(7):2068-73.
14. Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica. 2011;96(3):454-8.
15. Marchetti M, Carobbio A, Capitoni E. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review. Am J Hematol. 2018;93(5):698-703.
16. Todisco G, Manshouri T, Verstovsek S, et al. Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics. Leuk Lymphoma. 2016 ; 57(5): 1054–1059.
17. Kimura A, Hyodo H, Nakata Y, et al. Chronic lymphocytic leukemia associated with bone marrow fibrosis: Possible role of interleukin 1 alpha in the pathogenesis. Am J Hematol. 1993;43:47–50.
Files
IssueVol 15, No 4 (2021) QRcode
SectionCase Report(s)
DOI https://doi.org/10.18502/ijhoscr.v15i4.7481
Keywords
Essential thrombocythemia; Janus Kinase 2 (JAK2) V617F; Lymphoproliferative disorder
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Butt A, Quddus R, Ali N. Concomitant Essential Thrombocythemia and Mature B -Lymphoproliferative Disorder in a Patient. Int J Hematol Oncol Stem Cell Res. 2021;15(4):255-259.